Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast ChinaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiota composition between 51 Parkinson's disease (PD) patients and 48 healthy controls, mostly spouses, in Northeast China. They asked whether microbiota differences exist and which clinical or dietary factors track with them.
How was it studied?
Stool samples underwent 16S rRNA gene sequencing to measure species richness, alpha- and beta-diversity, and taxon-level abundance. A subset of 42 patients and 23 controls also completed a food frequency questionnaire, and Spearman correlation linked microbiota abundance to clinical scores including UPDRS, NMSQ, and SCOPA-AUT.
What did they find?
PD patients had lower species richness, phylogenetic diversity, and beta-diversity than controls. The most consistent change across multiple analyses was increased Akkermansia and decreased Lactobacillus in PD patients, and PD-related clinical severity scores correlated most strongly with taxa abundance shifts.
Why it matters
Akkermansia has been linked to thinning of the intestinal mucus barrier and increased permeability, while Lactobacillus supports mucin production and short-chain fatty acid output, so these shifts may relate to gut barrier changes described in PD. The authors note regional diet, including fermented Suan Cai, may explain why some findings diverge from PD microbiome studies in other countries.